Henry Ji - 08 Oct 2025 Form 4 Insider Report for Scilex Holding Co (SCLX)

Reporting relationship: CEO and President, Director
Issuer ticker: SCLX
Reported as of: 08 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Oct 2025, 08:42:24 UTC
Prior SEC filing: 23 Sep 2025
Next SEC filing: 20 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Ma, as Attorney-in-Fact

Key filing fact

Henry Ji filed Form 4 for Scilex Holding Co (SCLX) on 09 Oct 2025.

Key facts

This page summarizes Henry Ji's Form 4 filing for Scilex Holding Co (SCLX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Oct 2025, 08:42.

Change

Previous filing in this sequence was filed on 23 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001470981 Primary reporting owner

Ji Henry

Relationship: CEO and President, Director
Address: C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO
Signature: /s/ Stephen Ma, as Attorney-in-Fact
Signature date: 09 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCLX transaction Derivative

Incentive Stock Option (right to buy)

Award

Transaction value: $0
Shares: +120,000
Change %
Price: $0.000000
Shares after: 120,000
Date: 08 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $17.58
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Notwithstanding the preceding sentence, the shares of Common Stock subject to the Option will not be exercisable until such date as the Issuer's outstanding indebtedness under the Senior Secured Promissory Note issued by the Issuer to Oramed Pharmaceuticals, Inc. on September 21, 2023 and the Tranche B Senior Secured Convertible Notes issued by the Issuer to each of Oramed Pharmaceuticals, Inc., Nomis Bay Ltd., 3i LP and BPY Limited, has been repaid in full.